Article
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
Blood - 20 Oct 2011
Kojima Kensuke, McQueen Teresa, Chen Ye, Jacamo Rodrigo, Konopleva Marina, Shinojima Naoki, Shpall Elizabeth, Huang Xuelin, Andreeff Michael
Abstract excerpt
Fms-like tyrosine kinase-3 (FLT3) inhibitors have been used to overcome the dismal prognosis of acute myeloid leukemia (AML) with FLT3 mutations. Clinical results with FLT3 inhibitor monotherapy have shown that bone marrow responses are commonly less pronounced than peripheral blood responses. We investigated the role of p53 in bone marrow stromal cells in stromal cell-mediated resistance to FLT3 inhibition in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.